Millennium Management LLC Purchases Shares of 29,149 Atossa Therapeutics, Inc. (NASDAQ:ATOS)

Millennium Management LLC purchased a new stake in Atossa Therapeutics, Inc. (NASDAQ:ATOS) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 29,149 shares of the company’s stock, valued at approximately $28,000.

Several other institutional investors and hedge funds also recently modified their holdings of ATOS. Gallagher Capital Advisors LLC acquired a new position in Atossa Therapeutics during the fourth quarter worth $25,000. Intech Investment Management LLC boosted its stake in shares of Atossa Therapeutics by 224.0% during the 4th quarter. Intech Investment Management LLC now owns 62,844 shares of the company’s stock worth $59,000 after buying an additional 43,449 shares during the last quarter. Virtu Financial LLC boosted its stake in shares of Atossa Therapeutics by 311.1% during the 4th quarter. Virtu Financial LLC now owns 208,196 shares of the company’s stock worth $197,000 after buying an additional 157,549 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Atossa Therapeutics by 141.4% in the 4th quarter. JPMorgan Chase & Co. now owns 361,296 shares of the company’s stock valued at $341,000 after acquiring an additional 211,654 shares in the last quarter. Finally, Wells Fargo & Company MN increased its position in shares of Atossa Therapeutics by 30.7% in the fourth quarter. Wells Fargo & Company MN now owns 71,720 shares of the company’s stock valued at $68,000 after acquiring an additional 16,853 shares during the last quarter. 12.74% of the stock is owned by institutional investors and hedge funds.

Atossa Therapeutics Stock Performance

ATOS opened at $0.83 on Friday. The stock has a fifty day moving average of $0.80 and a 200-day moving average of $0.85. The company has a market capitalization of $107.28 million, a P/E ratio of -3.78 and a beta of 0.92. Atossa Therapeutics, Inc. has a fifty-two week low of $0.55 and a fifty-two week high of $1.66.

Atossa Therapeutics (NASDAQ:ATOS) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.05) EPS for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. On average, equities research analysts predict that Atossa Therapeutics, Inc. will post -0.22 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ATOS has been the subject of several analyst reports. Ascendiant Capital Markets raised their target price on shares of Atossa Therapeutics from $7.25 to $7.50 and gave the company a “buy” rating in a research note on Friday, June 6th. HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Atossa Therapeutics in a research note on Wednesday, March 26th. Finally, Craig Hallum raised shares of Atossa Therapeutics to a “strong-buy” rating and set a $4.00 price objective for the company in a research report on Thursday, June 5th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.17.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.